Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Pluvicto is a targeted radioligand therapy, meaning it uses radioactive atoms to deliver radiation to targeted cells, fighting cancer while limiting damage to the surrounding tissues.

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

After just one Pluvicto treatment earlier this year, bloodwork showed Coy's cancer level plummeted. Not everyone responds that well to Pluvicto, and things could always change for Coy.

New report finds colorectal cancer rising among U.S. adults under 55 04:17. Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...

Leqvio and Pluvicto are key assets in Novartis’ portfolio to drive near- and mid-term growth. In the first quarter, the Swiss pharma saw sales grow 5% at constant currencies to $12.5 billion ...

“Pluvicto is a radiation treatment, but not with a beam, it’s given with an IV into the body, and it’s a very sophisticated concept,” said Dr. Gary Kirsh, a urologist at The Urology Group.